阿列克替尼
医学
间变性淋巴瘤激酶
肺癌
肿瘤科
内科学
表皮生长因子受体
怀孕
埃罗替尼
腺癌
卡铂
酪氨酸激酶抑制剂
癌症研究
化疗
癌症
生物
恶性胸腔积液
遗传学
顺铂
作者
Florence T.H. Wu,Rebekah Rittberg,Kun Young Lim,Cheryl Ho
出处
期刊:Case Reports
[BMJ]
日期:2024-03-01
卷期号:17 (3): e255575-e255575
标识
DOI:10.1136/bcr-2023-255575
摘要
Management of cancer during pregnancy requires careful consideration of risks and benefits from maternal and fetal perspectives. For advanced lung adenocarcinomas, with no targetable driver mutations, there is evidence-based guidance on the use of carboplatin-paclitaxel chemotherapy after first trimester. In contrast, for epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged metastatic lung adenocarcinomas, there is a paucity of clinical data on the safety of EGFR and ALK tyrosine kinase inhibitors to mother and fetus for official guidelines to recommend the use of these otherwise-first-line therapies in pregnancy. Considering this knowledge gap, we present a case of a young gravida 1 para 0 (G1P0) woman who continued alectinib 300 mg oral two times per day for ALK-rearranged metastatic lung adenocarcinoma throughout all 36 weeks of her pregnancy and delivered a healthy baby at term via caesarean section (C-section).
科研通智能强力驱动
Strongly Powered by AbleSci AI